Sadaf S. Khan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Sadaf S. Khan has a total of 1 co-authors. Here are the top co-authors by number of shared publications:
Susan E. Quaggin
Division of Nephrology and Hypertension, Feinberg School of Medicine, Northwestern University, 303 East Superior Lurie Building, 10th Floor, Chicago, IL, 60611, USA
1 shared publication
Latest Publications
- 12 October 2015
- Published by Springer Nature in Current Diabetes Reports
- Vol. 15 (12) , 111
Therapies on the Horizon for Diabetic Kidney Disease
Diabetic nephropathy is rapidly becoming the major cause of end-stage renal disease and cardiovascular mortality worldwide. Standard of care therapies include strict glycemic control and blockade of the renin-angiotensin-aldosterone axis. While these treatments slow progression of diabetic nephropathy, they do not arrest or reverse it. Newer therapies targeting multiple molecular pathways involved in renal inflammation, fibrosis, and oxidative stress have shown promise in animal models. Subsequently, many of these agents have been investigated in clinical human trials with mixed results. In this review, we will discuss recent findings of novel agents used in the treatment of diabetic nephropathy.
- 12 October 2015
- Published by Springer Nature in Current Diabetes Reports
- Vol. 15 (12) , 111
Therapies on the Horizon for Diabetic Kidney Disease
Diabetic nephropathy is rapidly becoming the major cause of end-stage renal disease and cardiovascular mortality worldwide. Standard of care therapies include strict glycemic control and blockade of the renin-angiotensin-aldosterone axis. While these treatments slow progression of diabetic nephropathy, they do not arrest or reverse it. Newer therapies targeting multiple molecular pathways involved in renal inflammation, fibrosis, and oxidative stress have shown promise in animal models. Subsequently, many of these agents have been investigated in clinical human trials with mixed results. In this review, we will discuss recent findings of novel agents used in the treatment of diabetic nephropathy.